文献速递神经核医学核素与放射性配体治疗

靶向α治疗中使用213Bi-物质P类似物局部注射可延长继发性胶质母细胞瘤生存期

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-04-30

在波兰华沙医科大学已接受靶向α治疗的50例不同亚型胶质瘤患者中,报告9例继发性胶质母细胞瘤患者的数据。术后放化疗后复发肿瘤经腔内注射1–6剂0.9–2.3 GBq的213Bi-DOTA-SP,间隔2个月;同时共注射68Ga-DOTA-SP用于PET/CT评估生物分布,MRI监测治疗反应。治疗耐受良好,仅见轻度短暂不良反应;自α治疗开始的中位无进展生存期和总生存期分别为5.8个月和16.4个月,自首次诊断的中位总生存期为52.3个月。

要点

  • 9例继发性胶质母细胞瘤患者接受腔内注射1–6剂0.9–2.3 GBq的213Bi-DOTA-SP,间隔2个月。
  • 治疗用量1.4–9.7 GBq(中位5.8 GBq),耐受良好,仅见轻度短暂不良反应,主要为短暂局灶性水肿反应所致头痛。
  • 自α治疗开始的中位无进展生存期5.8个月、总生存期16.4个月;自首次诊断中位总生存期52.3个月。

核心结论

  • 作者认为,使用213Bi-DOTA-SP对继发性胶质母细胞瘤进行靶向α治疗安全且耐受良好,可能发展为继发性胶质母细胞瘤有前景的新型治疗选择。

研究设计与样本

  • 在波兰华沙医科大学截至报告时已接受靶向α治疗的50例不同亚型胶质瘤患者中,报告9例继发性胶质母细胞瘤患者的数据。
  • 复发肿瘤在手术、化疗和放疗后,经腔内注射1–6剂0.9–2.3 GBq的213Bi-DOTA-[Thi8,Met(O2)11]-物质P(213Bi-DOTA-SP),间隔2个月。
  • 68Ga-DOTA-[Thi8,Met(O2)11]-物质P(68Ga-DOTA-SP)与治疗剂量共注射,用PET/CT评估生物分布;用MRI监测治疗反应。

主要发现

  • 治疗用量范围为1.4–9.7 GBq(中位5.8 GBq)的213Bi-DOTA-SP,耐受良好,仅见轻度短暂不良反应,主要为短暂局灶性水肿反应所致头痛。
  • 自α治疗开始的中位无进展生存期为5.8个月,中位总生存期为16.4个月。
  • 自首次诊断的中位总生存期为52.3个月。
  • 9例中2例在α治疗开始后39个月和51个月仍存活。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma multiforme (GBM), the most common malignant brain tumor, mainly manifests as a primary de novo and less frequently as a secondary glial neoplasm. GBM has been demonstrated to overexpress the NK-1 receptor and substance P can be used as a ligand for targeted therapy. Alpha emitters, e.g. 213Bi, that deposit their high energy within a short range allow the selective irradiation of tumor cells while sparing adjacent neuronal structures. MATERIAL AND METHODS: Among 50 glioma patients of different subtypes that have to date been treated with targeted alpha therapy at the Medical University Warsaw, we report here the data on nine patients with secondary GBM. Following surgery, chemo- and radiotherapy, recurrent GBM was treated by intracavitary injection of 1-6 doses of 0.9-2.3 GBq 213Bi- DOTA-[Thi8,Met(O2)11]-substance P (213Bi-DOTA-SP) in 2-month intervals. 68Ga-DOTA-[Thi8,Met(O2)11]-substance P (68Ga-DOTA-SP) was co-injected with the therapeutic doses to assess biodistribution using PET/CT. Therapeutic response was monitored with MRI. RESULTS: Treatment with activities ranging from 1.4 to 9.7 (median 5.8) GBq 213Bi- DOTA-SP was well tolerated with only mild transient adverse reactions, mainly headaches due to a transient perfocal edema reaction. The median progression free survival and overall survival time following the initiation of alpha therapy was 5.8 and 16.4 months, respectively. The median overall survival time from the first diagnosis was 52.3 months. Two out of nine patients are still alive 39 and 51 months, respectively, after the initiation of the therapy. CONCLUSIONS: Targeted alpha therapy of secondary GBM with 213Bi-DOTA-SP is safe and well tolerated and may evolve as a promising novel therapeutic option for secondary GBM.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Krolicki L, Bruchertseifer F, Kunikowska J, et al. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue. Eur J Nucl Med Mol Imaging. 2018. PMID: 29713762. doi:10.1007/s00259-018-4015-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。